

Supplementary Materials S1: Questionnaire : Long-term health effects of COVID-19 in Tunisia, 2020/2021

Oral Informed consent :

Date of the phone-survey: [DD/MM/Years]

Investigator name: [Consultant name]

Patient identity: [First name] [Last name], [Age]

My name is [investigator name] and I work at the National Observatory of New and Emerging Diseases, Ministry of Health, Tunis, Tunisia. You were infected by SARS-Cov-2. We call you today to monitor your health status after COVID-19 disease.

If you agree, I will ask you some questions that will be used to orientate your needs of medical monitoring specific to your COVID-19 disease.

May I continue this interview ? [YES / NO]

If no, why? [text]

1-Consultant's informations :

 Date of the teleconsultation: DD /MM/Years

 Consultant name:

 Consultant phone :

2-Patient's general informations :

 Identification number (ID) :

 Gender : Male ☐; Female ☐

 Date of birth : DD /MM/Years ; Age (years)

 Governorate of residence :

 Health care worker : Yes ☐ ; No ☐

 Occupation level :

*Worker ☐

*Middle management ☐

*Senior ☐

*Unemployed ☐

*Student ☐

 Education : Illetrate ☐

Primary, secondary, post secondary level ☐

Universitary level ☐

3-Patient's clinical characteristics and life style :



If Yes, type of comorbidities:



4-COVID-19 related data :

-

-

Anorex

Weigh

Tiredn

Joint o

Fever |

Rash ☐

Post-exertional malaise (Symptoms that get worse after physical or mental activities) ☐:

Changes in menstrual period cycles ☐

Hair loss ☐

Vertigo ☐

▪ **Respiratory symptom :**

Difficulty breathing or shortness of breath (New onset dyspnea) ☐

Wheezing ☐

New onset cough ☐

New onset allergies ☐

Abnormal lung CT-scan since discharge ☐

▪ **Heart symptoms :**

Tachycardia/palpitations ☐

Orthostatic hypotension ☐

Chest discomfort, Chest pain ☐

▪ **Neurologic signs :**

Headache ☐

Paresthesia (Pins-and-needles feeling) ☐

Change in smell or taste ☐

▪ **Cognitive signs :**

Memory losses ☐

Slowness for reasoning, activity planification or problem solving ☐

Concentration, attention or thinking difficulties (brain fog) ☐

Sleep problems (insomnia) ☐

Mood changes ☐ If Yes : duration (days) :

Symptoms of post-traumatic stress disorder ☐

Depression ☐

▪ **Gastrointestinal signs :**

Loss of appetite ☐

Diarrhoea ☐

Constipation ☐

Acid reflux ☐

▪ Number of symptoms first week of illness : 1 ☐ ; 2-4 ☐ ; ≥ 5 ☐

▪ Duration of symptoms : < 10 d ☐

10-28 d ☐

> 1 month ☐

> 2 months ☐

> 3 months ☐

> 6 months ☐

▪ Oxygenotherapie supplementation : Yes ☐ ; No ☐

▪ Hospitalization during acute infection phase : Yes ☐ ; No ☐

If yes : duration of hospitalization (days) :

▪ Service of hospitalization ICU ☐ ; other COVID-19 isolation service

▪ Duration of hospitalization in ICU : days

▪ Complications during Acute infection : Yes ☐ ; No ☐

If yes : Type of complications :

▪ Pulmonary embolism ☐

▪ Acute respiratory failure ☐

▪ Acute cardiac failure ☐

▪ Specific treatment received in acute infection Yes ☐ ; No ☐

Severity grade of acute infection :

Asymptomatic ☐

Mild/Moderate ☐

Critical/Severe ☐

If Yes : Antibiotic (Zithromax) ☐

Hydroxychloroquine ☐

Corticosteroids ☐

Anticoagulation ☐

✚ Date of recovery from acute illness : DD /MM/Years

✚ COVID-19 vaccination : Yes ☐ ; No ☐

if yes : Name of vaccine :

Date of vaccination :

5-Long COVID-19's symptoms : For participants who said yes in duration of symptoms >28d

✚ Types of symptoms :

▪ **General signs :**

Anorexia ☐ If Yes : duration (days) :

Weight loss ☐ If Yes : duration (days) :

Tiredness or fatigue ☐ If Yes : duration (days) :

Joint or muscle pain ☐ If Yes : duration (days) :

Fever ☐ If Yes : duration (days) :

Rash ☐ If Yes : duration (days) :

Diarrhea ☐ If Yes : duration (days) :

Post-exertional malaise (Symptoms that get worse after physical or mental activities) ☐ If Yes :
duration (days) :

Changes in menstrual period cycles ☐ If Yes : duration (days) :

▪ **Respiratory symptom :**

Difficulty breathing or shortness of breath (New onset dyspnea) ☐ If Yes : duration (days) :

New onset cough ☐ If Yes : duration (days) :

Abnormal lung CT-scan since discharge ☐ If Yes : duration (days) :

▪ **Heart symptoms :**

Heart palpitations ☐ If Yes : duration (days) :

Orthostatic hypotension ☐ If Yes : duration (days) :

Chest discomfort, Chest pain ☐ If Yes : duration (days) :

▪ **Neurologic signs :**

Headache ☐ If Yes : duration (days) :

Paresthesia (Pins-and-needles feeling) ☐ If Yes : duration (days) :

Change in smell or taste ☐ If Yes : duration (days) :

▪ **Cognitive signs :**

Memory losses ☐ If Yes : duration (days) :

Slowness for reasoning, activity planification or problem solving ☐ If Yes : duration (days) :

Concentration, attention or thinking difficulties (brain fog) ☐ If Yes : duration (days) :

Sleep problems ☐ If Yes : duration (days) :

Mood changes ☐ If Yes : duration (days) :

Symptoms of post-traumatic stress disorder ☐ If Yes : duration (days) :

Depression ☐ If Yes : duration (days) :

▪ **Gastrointestinal signs :**


Loss of appetite ☐ If Yes : duration (days) :

Diarrhoea ☐ If Yes : duration (days) :

Constipation ☐ If Yes : duration (days) :


Acid reflux ☐ If Yes : duration (days) :

Supplementary Materials S2: ROC curve for COVID-19 acute infection, long COVID study, Tunisia, 2022 ($n= 416$)



Les segments diagonaux sont générés par les liens.

Supplementary Materials S3: Heat map for long COVID symptoms, long COVID cross-sectional study, Tunisia, 2020/2021 (n= 416)



Supplementary Materials S4: Checking of representativeness of the study population according to the stratification criteria, long-COVID cross-sectional study, Tunisia, 2020–2021

Region	Source database	Study population	p-value
North	204468	181	0.8
Center	179186	157	
South	96089	78	
Total	479743	416	

Age group (years)	Source database	Study population	p-value
0-17	35269	30	0.4
18-64	386556	345	
65+	57917	41	
Total	479743	416	